Drug Trial Radar · NCT03732807
PF-06651600 for the Treatment of Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
718
Actual
Start
Dec 3, 2018
Primary completion
Dec 31, 2020
Study completion Jun 24, 2021
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Conditions
- Alopecia Areata
Interventions
PF-06651600 Induction DoseDrug
Oral tablets taken once daily (QD)
PF-06651600 Maintenance Dose #1Drug
Oral tablets taken QD
PF-06651600 Maintenance Dose #2Drug
Oral tablets taken QD
PF-06651600 Maintenance Dose #3Drug
Oral tablets taken QD
PlaceboDrug
Oral tablets taken QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24Time frame: Week 24
Locations
155 sites in 18 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham Hospital Outreach Lab
Birmingham, Alabama
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
Mosaic Dermatology
Beverly Hills, California
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center
Irvine, California
Dermatology Specialists, Inc.
Murrieta, California
University of California, San Francisco
San Francisco, California
Kaiser Permanente Clinical Trials Unit
San Francisco, California
Southern California Dermatology, Inc.
Santa Ana, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Colorado Hospital Clinical and Translational Research Center
Aurora, Colorado
University of Colorado Hospital Outpatient Pavillion
Aurora, Colorado
Yale School of Medicine
New Haven, Connecticut
Church Street Research Unit
New Haven, Connecticut
Medstar Georgetown University Hospital Center-Department of Otolaryngology
Washington D.C., District of Columbia
Medstar Washington Hospital Center-Claude Nogay Research Pharmacy
Washington D.C., District of Columbia
Medstar Washington Hospital Center
Washington D.C., District of Columbia
Medstar Georgetown University Hospital Center-Department of Pediatrics
Washington D.C., District of Columbia
Siperstein Dermatology Group
Boynton Beach, Florida
Park Avenue Dermatology
Orange Park, Florida
ForCare Clinical Research
Tampa, Florida
Advanced Clinical Research
Meridian, Idaho
Northwestern Medical Group
Chicago, Illinois
Northwestern Medicine Diagnostic Testing Center
Chicago, Illinois
Northwestern Medicine
Chicago, Illinois
Northwestern Memorial Hospital, Investigational Research Pharmacy
Chicago, Illinois
Northwestern University
Chicago, Illinois
NorthShore University HealthSystem
Skokie, Illinois
Southern Illinois University School of Medicine
Springfield, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
University of Iowa Hospitals and Clinics; Department of Pharmacy-IDS;
Iowa City, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Medstar Georgetown University Hospital - Department of Dermatology
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Minnesota Department of Dermatology
Minneapolis, Minnesota
University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
Minneapolis, Minnesota
Skin Specialists, PC
Omaha, Nebraska
The Dermatology Group, P.C.
Verona, New Jersey
NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.